Reactive Oxygen Species and Nuclear Factor Erythroid 2-Related Factor 2 Activation in Diabetic Nephropathy: A Hidden Target

Shaaban Abdo, Shao-Ling Zhang, and John S.D. Chan
Department of Medicine, University of Montreal and Research Center Hospital of QC, Canada

Abstract

Hyperglycemia, oxidative stress and renin-angiotensin system (RAS) dysfunction have been implicated in diabetic nephropathy (DN) progression, but the underlying molecular mechanisms are far from being fully understood. In addition to the systemic RAS, the existence of a local intrarenal RAS in renal proximal tubular cells has been recognized. Angiotensinogen is the sole precursor of all angiotensins (Ang). Intrarenal reactive oxygen species (ROS) generation, Ang II level and RAS gene expression are up-regulated in diabetes, indicating that intrarenal ROS and RAS activation play an important role in DN. The nuclear factor erythroid 2-related factor 2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1) pathway is one of the major protective processes that occurs in response to intracellular oxidative stress. Nrf2 stimulates an array of antioxidant enzymes that convert excessive ROS to less reactive or less damaging forms. Recent studies have, however, revealed that Nrf2 activation might have other undesirable effects in diabetic animals and in diabetic patients with chronic kidney disease. This mini-review summarizes current knowledge of the relationship between ROS, Nrf2 and intra renal RAS activation in DN progression as well as possible novel target(s) for DN treatment.

Keywords
Nrf2; Angiotensinogen expression; Renin-angiotensin system

Introduction

Diabetes is an epidemic disease that is imposing a heavy healthcare burden globally. Its incidence is continuing to rise unabated. According to recent estimates by the International Diabetes Federation, the number of people with diabetes will surge from 382 to 592 million in less than 25 years. Diabetes and its associated complications caused 5.1 million deaths in

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Corresponding author: John S.D. Chan, Department of Medicine, University of Montreal and Research Center Hospital of the University of Montreal (CRCHUM)-Tour Viger900 Saint Denis Street, Montreal, QC, Canada H2X 0A9, Tel: (15080) 5148908000; john.chan@umontreal.ca.

Disclosure
None declared.

No potential conflicts of interest relevant to this article were reported.
2013 [1]. Diabetic nephropathy (DN), a clinical syndrome, is the result of gluco-lipotoxicty. It impacts the kidneys, eliciting progressive renal insufficiency, persistent albuminuria, hypertension and decreased glomerular filtration rate (GFR) [2]. DN affects approximately one-third of people with type 1 or type 2 diabetes mellitus (T1D and T2D respectively) [3]. It is the most common cause of end-stage renal disease (ESRD) in the West and possibly throughout the world, accounting for more than 50% of all patients with ESRD. Although insulin and oral anti-diabetic drugs, along with diet and exercise, are the cornerstones of diabetes mellitus and DN treatment [4,5], their underlying mechanisms remain incompletely understood.

**The Renin-Angiotensin System (RAS)**

The RAS is a hormonal system that regulates sodium balance, body fluid homeostasis and arterial pressure [6]. All RAS components have been identified in the kidneys [7], including mRNA and protein of angiotensinogen (Agt), renin, angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2, angiotensin II (Ang II) receptor subtypes 1 and 2 (AT1R and AT2R) as well as Ang 1–7 receptor (MasR). In the kidneys, Agt is expressed predominantly in renal proximal tubular cells (RPTCs): it is converted into inactive Ang I by renin and then into biologically-active Ang II by ACE. Ang II could be further cleaved to Ang 1–7. Intrarenal RAS gene expression is elevated in diabetes [8], strongly indicating that intrarenal RAS activation plays a significant role in DN progression including interstitial tubule-fibrosis and tubular atrophy [9].

Hypertension usually accompanies diabetes mellitus, which increases kidney damage when normo-albuminuria evolves to macro-albuminuria [10]. Ang II, the main product of RAS activation, contributes to various physiological and pathological renal and cardiovascular mechanisms through AT1R stimulation [11]. It has been reported that early streptozotocin (STZ)-induced diabetes down-regulates rat kidney AT2R and increases AT1R [12]. Moreover, several studies have shown that AT2R expression is augmented by insulin treatment [13] and down-regulated by Ang II infusion or epidermal growth factor treatment [14]. Arresting the effects of RAS activation with either ACE inhibitors [15] to decrease Ang II production or with angiotensin-receptor blockers (ARBs) to block AT1R activation, leads to lower intraglomerular pressure [16], reduced systemic hypertension and, consequently, decreased renal interstitial fibrosis.

**Reactive Oxygen Species (ROS)**

Living organisms produce ROS as a result of normal cellular metabolism. ROS steady-state levels are required for cell proliferation, differentiation [17] and degradation of misfolded/damaged proteins by ubiquitin and 26S proteasome [18]. In contrast, excessive ROS production damages cellular components, such as DNA, proteins and lipids [19]. Superoxide (O2•−), hydrogen peroxide (H2O2) and nitric oxide are free radicals essential for normal physiological development, but also mediate cellular damage in disease states [20]. Cellular sources of ROS production include plasma membrane nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), intracellular cytosolic xanthine oxidase, peroxisomal oxidases, endoplasmic reticular oxidases and mitochondrial electron transport constituents.
Mitochondrial electron transport of aerobic respiration, considered to be the main source of ROS, has been implicated in many disorders [21, 22]. It has been estimated that 0.2 to 2% of the oxygen consumed by mitochondria is reduced to O2•− [23].

Oxidative stress occurs in cellular systems when the production of free radical moieties exceeds the antioxidant capacity of those systems, evoking a shift in balance between oxidants/antioxidants in favour of oxidants [24]. In certain pathological conditions, increased generation of ROS and/or antioxidant defence system depletion generate enhanced ROS activity and oxidative stress, resulting in tissue damage. Several systemic diseases, such as hypertension, diabetes mellitus, metabolic syndrome and infections, induce renal oxidative stress [25]. Excessive ROS production in the kidneys has been reported in different hypertensive animal models [26, 27], including Ang II-induced hypertensive rats [28], N-omega-nitro-L-arginine-induced hypertensive rats [29], Dahl salt-sensitive hypertensive rats [30] and spontaneously hypertensive rats [31].

### Nrf2 Activation and Redox Balance

Oxidative stress is the most common cause of tissue injury. In order to maintain redox homeostasis balance to prevent cellular damage, an intracellular antioxidant system, i.e., Nuclear factor erythroid 2-related factor 1–3 (Nrf 1–3), is activated to detoxify the potential harmful substance. Nrf1, Nrf2 and Nrf3 genes encode a member of the cap ‘n’ collar basic-region leucine zipper family, which is vital in regulating antioxidant gene expression [32], development and redox balance [33]. Nrf1 is an important player in redox balance during development [34]. Homozygous Nrf1 null mice die in utero [35], while Nrf2- and Nrf3-null mice develop normally with no obvious phenotypic differences compared to wild type controls [36, 37]. Nrf2-deficient female mice develop lupus-like autoimmune nephritis [38]. Nrf1 and Nrf2 deficiency, however, has been shown to culminate in early embryonic lethality and severe oxidative stress [39]. Nrf2 is a transcriptional factor consisting six evolutionarily highly conserved domains, Neh1–6 [40] that activates the transcription of an array of antioxidant genes [41]. Several reports showed that Nrf2 activation may protect against human disease such as cardiovascular disease [42], cancer [43], neurodegenerative diseases [44] and chronic kidney disease [45].

### Regulation of Nrf2 activation

Nrf2 activation is predominantly regulated by its cytosolic partner, Nrf2 adaptor or Kelch-like ECH-associated protein 1 (Keap1). Keap1 is a protein of five domains: two protein-protein interaction motifs, the Kelch domain, the intervening region (IVR), and the BTB domain [46]. Keap1 acts as a cytosolic repressor for Nrf2 in the cytoplasm. Several models have been proposed to understand the mechanism of Nrf2 activation. Under normal physiological conditions, the BTB domain of Keap1 interacts with the Neh2 domain of cytoplasmic Nrf2 and forms complexes with Cullin 3-based E3 ligase [47]. These complexes promote Nrf2 degradation via the ubiquitin proteasome system [48]. In response to oxidative stress or chemo-preventive compounds, Nrf2 dissociates from Keap1 and translocates to the nucleus [49]. However, if Keap 1 binds to other proteins, Nrf2 does not ubiquitinated but activated in a non-canonical, cysteine-independent manner. For example, Lau et al. [50] demonstrated...
that deregulation of autophagy pathway causes the accumulation of p62 (an autophagic protein) that directly interacts with Keap1, resulting in the inhibition of Keap1-mediated Nrf2 ubiquitination. In addition, Nrf2 has been shown to be regulated at transcriptional level, independent of the Keap1 mechanism. Studies by Kawak et al [51] demonstrated that Nrf2 undergoes autoregulation: Nrf2 binds to its own promoter and induce its own transcriptional activity. Post-translation modifications also play a significant role in Nrf2 function and localization. For example, Nrf2 phosphorylation by protein kinase C at serine 40 residue is critical signaling event to regulate cellular antioxidant response [52]. Furthermore, acetylation-deacetylation of the Nrf2 regulates its transcriptional activity and nucleocytoplasmic localization [53]. Natural or synthetic chemopreventive agents, such as curcumin, flavonoids, oltipraz, butylatedhydroxyanisole, and bardoxolone methyl stimulate Nrf2 activation and nuclear translocation. Within the nucleus, Nrf2 forms a heterodimer with Maf protein and bind to regulatory sequences in the promoter region of various genes, known as antioxidant response elements (AREs). A series of antioxidant and cellular protective genes containing AREs in their promoters have been identified; such as glutathione peroxidase, superoxide dismutase, catalase (Cat), heme-oxygenase, NADPH-quinoneoxidoreductase 1 and glutamate-cysteine ligase [54,55]. Moreover, it has been found that activation of Nrf2 signaling attenuates NFKappaB-inflammatory response and elicits apoptosis [56].

Recent studies, however, revealed that Nrf2 may also affect none-oxidant genes expression. For example, Pendyala et al. [57] demonstrated in human lung endothelium, by chromatin-immunoprecipitation assay, that Nrf2 binds to ARE regions in NADPH oxidase-4 (Nox4) gene promoter and up-regulates its activity. NADPH oxidase-1, -2 and -4 (Nox1, Nox2 and Nox4) have also been shown to be expressed in the renal cortex and Nox4 is the most common isoform expressed in the kidneys [58,59]. Nox4 contributes to basal ROS production through its constitutive activity and increases ROS generation when stimulated by Ang II, glucose, and growth factors [60–62]. Our study in the renal proximal tubules (RPTCs) of diabetic Akita mice (a murine model of T1D) has disclosed that Nrf2 translocates to the nucleus with markedly enhanced NADPH oxidase activity as well as Nox4 mRNA expression compared to non-Akita mice, suggesting that Nrf2 induction of Nox4 expression and activity might be responsible, at least in part, for elevated ROS levels [63]. Intriguingly, these changes are normalized by overexpressing catalase (Cat) in RPTCs of Akita mice, lessening Nrf2 translocation to the nucleus [63]. These observations indicated that constitutive Nrf2 accumulation does not necessary induce absolute protection from environmental influences. Indeed, study has shown that hyperoxia stimulates Nrf2 translocation to the nucleus, and Nrf2 knockdown of Nrf2 gene expression by small interfering RNA (siRNA) attenuates hyperoxia-induced Nox4 expression, suggesting that Nrf2 may up-regulates Nox4 gene expression in certain physiological conditions [57].

**Nrf2 expression in diabetic kidneys**

Many studies demonstrated a beneficial effect of Nrf2 activation in none-diabetic kidney. Shelton et al. [64] reported that Nrf2 activation protects the kidney against oxidative stress that results from ischemic-reperfusion [65,66], renal injury caused by excessive heavy metals [67,68], and ameliorate cyclosporine A nephrotoxicity [69].
In animals with streptozotocin (STZ)-induced diabetes, Nrf2 ablation appears to worsen inflammation, oxidative stress, and nephropathy [70,71]. Moreover, dietary supplementation with sulforaphane or cinnamic aldehyde (Nrf2 activators) reduces albuminuria and renal oxidative damage in STZ-induced diabetic mice [71,72]. It also improves glucose control, lowers plasma triglyceride and FFA levels, decreases hepatic lipid accumulation and inflammation in both high-fat diet-induced and genetic mouse models of obesity and diabetes [73,74]. Thus, Nrf2 appears to be cytoprotective in none-diabetic and diabetic animal models.

**Nrf2 activation in human chronic kidney disease (CKD)**

A phase II trial of bardoxolone methyl (a Nrf2 activator) involving patients with advanced CKD and diabetes was carried out based on compelling evidence of the association between oxidative stress, inflammation and DN progression. Pergola et al. [75] initiated a small clinical trial of 227 T2D patients with moderate to severe CKD (BEAM study) and observed that bardoxolone methyl treatment increased estimated GFR in a dose-dependent manner in patients at 24 weeks with persistence up to 52 weeks. These encouraging data motivated de Zeeuw et al. [76] to investigate the effect of bardoxolone methyl in a phase III clinical trial in 2,185 patients from different countries with stage III CKD and T2D (BEACON Study). However, the trial was terminated early in October 2012 because bardoxolone methyl treatment neither improved renal function nor reduced the risk of ESRD, but was actually associated with increased risk of cardiovascular death. In fact, bardoxolone methyl-treated patients presented significant increment of estimated GFR, blood pressure (BP) and urinary albumin-to-creatinine ratio, with decreased body weight in comparison to the placebo group, and acquired a higher risk of cardiovascular events.

Studies were performed in Zucker diabetic fatty (ZDF) rats, a T2D model, to confirm the potential effects of bardoxolone methyl in DN. Zoja et al. [77] reported that ZDF rats receiving the bardoxolone methyl analogue RTA 405 presented DN deterioration impacting the liver. In contrast, a study of RTA 405 and dh404 sponsored by Reata Pharmaceuticals via Biomodels LLC in ZDF rats showed heightened urinary albumin/creatinine ratios with both compounds, but no adverse effects in the liver [78]. Inconsistencies between these two studies were observed. Subsequent analysis by Reata Pharmaceuticals revealed the presence of unknown impurities in RTA 405 that they had supplied for both studies. The concentrations of these impurities were very low, indicating that they might have been extremely toxic. Unfortunately, no further work on ‘pure’ RTA 405 has been reported. Whether Nrf2 activation worsens human CKD progression remains uncertain. Despite such conflicting results, there is still evidence that Nrf2-dependent events are protective against DN progression [70,71,73,74]. These findings led us to investigate whether Nrf2 activator treatment would have adverse side-effects in the kidneys by itself or whether Nrf2 pathway activation would elevate BP and cause kidney injury. To answer this question, we explored the relationship between renal Nrf2 activation and Agt gene expression in the RPTs of wild type mice since we previously reported that high glucose stimulated Agt gene expression via ROS generation [79] and that transgenic mice overexpressing Agt in their RPTCs exhibited hypertension, albuminuria and renal injury [80]. Indeed, we found that oltipraz (a Nrf2 activator) administration heightened both Nrf2 and renal Agt gene expression. Moreover,
deletion of Nrf2-response element (RE) sites in the Agt promoter prevented oltipraz stimulation of Agt gene transcription in RPTCs [63]. These observations strongly suggest that Nrf2 may play dual roles, with stimulation of both antioxidant and hypertensinogenic genes, such as Agt, as illustrated in the schematic Figure 1 below:

In conclusion, clinical studies have shown that Nrf2 activation by bardoxolone methyl increases systemic hypertension aggravates urinary albumin excretion and augments the risk of cardiovascular death in type II diabetic patients with advanced CKD [76]. These observations suggest that Nrf2 over-activation may not always exhibit beneficial in diabetes. Hyperglycemia-induction of ROS generation and chronic activation of Nrf2 signaling may induce intrarenal RAS activation, lending to systemic hypertension, albuminuria and tubular apoptosis and atrophy, further aggravate nephropathy progression. Thus, blocking chronic Nrf2 activation in diabetic kidneys would be a novel therapeutic target for DN treatment. Indeed, the recent study by Tan et al [81] demonstrated that low doses of dh404 lessened and high doses worsened diabetes-associated atherosclerosis and kidney disease in STZ-induced diabetic apoE−/− mice as well as the study by Vaziri et al. [82] demonstrated that in diabetic obese Zucker rats, low doses of dh404 restore Nrf2 activity and ameliorate kidney injury whereas high doses of dh404 reinforce proteinuria, renal dysfunction and histological abnormalities. These observations strongly suggest the possible dual function of Nrf2 activation in the diabetic kidney, depending on the level of Nrf2 activation in diabetes.

Acknowledgments

This work was supported by grants from the Canadian Institutes of Health Research (CIHR, MOP 93650 and MOP 16088 to J.S.D.C. and MOP-86450 to S.L.Z.). Editorial assistance was provided by the CRCHUM Research Support Office and Ovid M. Da Silva.

Abbreviations

ACE  Angiotensin-Converting Enzyme
Agt  Angiotensinogen
Ang II  Angiotensin II
Ang 1–7  Angiotensin 1–7
ARE  Antioxidant Responsive Element
AT1R  Ang II subtype 1 receptor
AT2R  Ang II subtype 2 receptor
BP  Blood Pressure
Cat  Catalase
CKD  Chronic Kidney Disease
DN  Diabetic Nephropathy
ESRD  End Stage Renal Disease
GFR Glomerular Filtration Rate
HG High Glucose
hnRNP F and hnRNP K Heterogeneous Nuclear Ribonucleoproteins F and K
H2O2 Hydrogen Peroxide
Keap1 Kelch-like ECH-associated Protein 1
NADPH oxidase Nicotinamide Adenine Dinucleotide Phosphate Oxidase
Nrf2 Nuclear Factor Erythroid 2-Related Factor 2
O2•− Superoxide
RAS Renin-Angiotensin System
Res Responsive Elements
ROS Reactive Oxygen Species
RPTs Renal Proximal Tubules
Runx2 Runt-Related Transcription Factor 2
RPTCs Renal Proximal Tubular Cells
STZ Streptozotocin
T1D and T2D Type 1 and Type 2 Diabetes Mellitus
ZDF Zucker diabetic fatty rats

References
1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103:137–149. [PubMed: 24630390]
2. Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis. 2011; 18:28–41. [PubMed: 21224028]
3. Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011; 170:1–7. [PubMed: 21659752]
4. Fonseca VA, Kulkarni KD. Management of type 2 diabetes: oral agents, insulin, and injectables. J Am Diet Assoc. 2008; 108:S29–33. [PubMed: 18358251]
5. Hayes C, Kriska A. Role of physical activity in diabetes management and prevention. J Am Diet Assoc. 2008; 108:S19–23. [PubMed: 18358249]
6. Johnston CI. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens Suppl. 1992; 10:S13–26.
7. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59:251–287. [PubMed: 17878513]
8. Lai KN, Leung JC, Lai KB, To WY, Yeung VT, et al. Gene expression of the renin-angiotensin system in human kidney. J Hypertens. 1998; 16:91–102. [PubMed: 9533422]
9. Chawla T, Sharma D, Singh A. Role of the renin angiotensin system in diabetic nephropathy. World J Diabetes. 2010; 1:141–145. [PubMed: 21537441]

10. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007; 18:1353–1361. [PubMed: 17329575]

11. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst. 2010; 11:33–36. [PubMed: 19861347]

12. Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol. 2001; 280:F254–265. [PubMed: 11208601]

13. Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol. 2006; 291:H787–796. [PubMed: 16565309]

14. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998; 83:1182–1191. [PubMed: 9851935]

15. Lewis E, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456–1462. [PubMed: 8413456]

16. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens. 2008; 21:922–929. [PubMed: 18535536]

17. Chung JS, Lee SB, Park SH, Kang ST, Na AR, et al. Mitochondrial reactive oxygen species originating from Romo1 exert an important role in normal cell cycle progression by regulating p27(Kip1) expression. Free Radic Res. 2009; 43:729–737. [PubMed: 19513905]

18. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P. Redox regulation of cell survival. Antioxid Redox Signal. 2008; 10:1343–1374. [PubMed: 18522489]

19. Valko M. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39:44–84. [PubMed: 16978905]

20. Maxwell SR, Lip GY. Free radicals and antioxidants in cardiovascular disease. Br J Clin Pharmacol. 1997; 44:307–317. [PubMed: 9354304]

21. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003; 552:1182–1191. [PubMed: 14747377]

22. Musatov A, Robinson NC. Susceptibility of mitochondrial electron-transport complexes to oxidative damage. Focus on cytochrome c oxidase. Free Radic Res. 2012; 46:1313–1326. [PubMed: 22856385]

23. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res. 2007; 100:460–473. [PubMed: 17332437]

24. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012; 5:9–19. [PubMed: 23268465]

25. Ozbek E. Induction of oxidative stress in kidney. Int J Nephrol. 2012; 2012:465897. [PubMed: 22577546]

26. Wilcox CS. Reactive oxygen species: roles in blood pressure and kidney function. Curr Hypertens Rep. 2002; 4:160–166.

27. Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008; 10:2047–2089. [PubMed: 18821850]

28. Haugen EN, Croatt AJ, Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int. 2000; 58:144–152. [PubMed: 10886559]

29. Rauchova H. Chronic N-acetylcysteine administration prevents development of hypertension in N(omega)-nitro-L-arginine methyl ester-treated rats: the role of reactive oxygen species. Hypertens Res. 2005; 28:475–82. [PubMed: 16156512]

30. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, et al. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol. 2004; 15:306–315. [PubMed: 14747377]
31. Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, et al. Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol. 2009; 36:750–755. [PubMed: 19298532]

32. McMahon M. The Cap’n’ Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 2001; 61:3299–307. [PubMed: 11309284]

33. Schultz MA, Abdel AB, Mondal Mageed D. The nrf1 and nrf2 balance in oxidative stress regulation and androgen signaling in prostate cancer cells. Cancers (Basel). 2010; 2:1354–78. [PubMed: 24281119]

34. Chen L, Kwong M, Lu R, Ginzingier D, Lee C, et al. Nrf1 is critical for redox balance and survival of liver cells during development. Mol Cell Biol. 2003; 23:4673–4686. [PubMed: 12808106]

35. Chan JY, Kwong M, Lu R, Chang J, Wang B, et al. Targeted disruption of the ubiquitous CNC-bZIP transcription factor, Nrf-1, results in anemia and embryonic lethality in mice. EMBO J. 1998; 17:1779–1787. [PubMed: 9501099]

36. Derjuga A, Gourley TS, Holm TM, Heng HH, Shivdasani RA, et al. Complexity of CNC transcription factors as revealed by gene targeting of the Nrf3 locus. Mol Cell Biol. 2004; 24:3286–3294. [PubMed: 15060151]

37. Chan K, Lu R, Chang JC, Kan YW. Nrf2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc Natl Acad Sci U S A. 1996; 93:13943–13948. [PubMed: 8943040]

38. Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, et al. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int. 2001; 60:1343–1353. [PubMed: 11576348]

39. Leung L, Kwong M, Hou S, Lee C, Chan JY. Deficiency of the Nrf1 and Nrf2 transcription factors results in early embryonic lethality and severe oxidative stress. J Biol Chem. 2003; 278:48021–48029. [PubMed: 12968018]

40. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999; 13:76–86. [PubMed: 9887101]

41. Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23:8137–8151. [PubMed: 14585973]

42. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004; 24:8477–8486. [PubMed: 15367669]

43. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24:7130–7139. [PubMed: 14585973]

44. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol. 2006; 26:221–229. [PubMed: 16354693]

J Diabetes Metab. Author manuscript; available in PMC 2015 July 22.
50. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010; 30:3275–3285. [PubMed: 20421418]
51. Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol. 2002; 22:2883–2892. [PubMed: 11940647]
52. Huang HC, Nguyen T, Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem. 2002; 277:42769–42774. [PubMed: 12198130]
53. Kawai Y. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J Biol Chem. 2011; 286:7629–40. [PubMed: 21196497]
54. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004; 36:1199–1207. [PubMed: 15110384]
55. Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008; 74:1526–39. [PubMed: 18937164]
56. Li W, Khor TO, Xu C, Shen G, Jeong WS, et al. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol. 2008; 76:1485–1489. [PubMed: 18694732]
57. Pendyala S, Moitra J, Kalari S, Kleeberger SR, Zhao Y, et al. Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: identification of functional antioxidant response elements on the Nox4 promoter. Free Radic Biol Med. 2011; 50:1749–1759. [PubMed: 21443946]
58. NlanduKhodo S, Dizin E, Sossauer G, Szanto I, Martin PY, et al. NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol. 2012; 23:1967–1976. [PubMed: 23100220]
59. Sedeek M, Nasrallah R, Touyz RM, Hebert RL. NADPH oxides, reactive oxygen species, and the kidney: friend and foe. J Am SocNephrol. 2013; 24:1512–1518.
60. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol RegulIntegr Comp Physiol. 2003; 285:R117–124.
61. Kim SM, Kim YG, Jeong KH, Lee SH, Lee TW, et al. Angiotensin II-induced mitochondrial Nox4 is a major endogenous source of oxidative stress in kidney tubular cells. PLoS One. 2012; 7:e39739. [PubMed: 22808054]
62. Xi G. Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCzeta-dependent manner in vascular smooth muscle cells. Diabetes. 2012; 6:104–13.
63. Abdo S. Catalase overexpression prevents nuclear factor erythroid 2-related factor 2 stimulation of renal angiotensinogen gene expression, hypertension, and kidney injury in diabetic mice. Diabetes. 2014; 63:3483–96. [PubMed: 24812425]
64. Shelton LM, Park BK, Copple IM. Role of Nrf2 in protection against acute kidney injury. Kidney Int. 2013; 84:1090–1095. [PubMed: 23783243]
65. Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 2009; 76:277–285. [PubMed: 19436334]
66. Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPAR3, and HO-1. Am J Physiol Renal Physiol. 2011; 300:F1180–1192. [PubMed: 21289052]
67. Calderon J, Ortiz-Perez D, Yanez L, Diaz-Barriga F. Human exposure to metals. Pathways of exposure, biomarkers of effect, and host factors. Ecotoxicol Environ Saf. 2003; 56:93–103. [PubMed: 12915143]
68. Chen J, Shaikh ZA. Activation of Nrf2 by cadmium and its role in protection against cadmium-induced apoptosis in rat kidney cells. ToxicolApplPharmacol. 2009; 241:81–89.
69. Shin DH, Park HM, Jung KA, Choi HG, Kim JA, et al. The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med. 2010; 48:1051–1063. [PubMed: 20996777]

70. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, et al. The protective role of Nrf2 in streptozocin-induced diabetic nephropathy. Diabetes. 2010; 59:850–860. [PubMed: 20103708]

71. Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, et al. Therapeutic potential of Nrf2 activators in streptozocin-induced diabetic nephropathy. Diabetes. 2011; 60:3055–3066. [PubMed: 22025779]

72. Cui W, Bai Y, Miao X, Luo P, Chen Q, et al. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation. Oxid Med Cell Longev. 2012; 2012:821936. [PubMed: 23050040]

73. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol. 2009; 620:138–144. [PubMed: 19698707]

74. Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem. 2010; 285:40581–40592. [PubMed: 20956520]

75. Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011; 365:327–336. [PubMed: 21699484]

76. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013; 369:2492–2503. [PubMed: 24206459]

77. Zoja C, Corna D, Nava V, Locatelli M, Abbate M, et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol. 2013; 304:F808–F819. [PubMed: 23136004]

78. Chin M, Lee CY, Chuang JC, Bumeister R, Wigley WC, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity. Am J Physiol Renal Physiol. 2013; 304:F1438–1446. [PubMed: 23594825]

79. Hsieh TJ, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, et al. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology. 2002; 143:2975–2985. [PubMed: 12130563]

80. Sachetelli S, Liu Q, Zhang SL, Liu F, Hsieh TJ, et al. RAS blockade decreases blood pressure and proteinuria in transgenic mice overexpressing rat angiotensinogen gene in the kidney. Kidney Int. 2006; 69:1016–1023. [PubMed: 16528251]

81. Tan SM. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetics. 2014; 6:3091–103.

82. Vaziri ND, Liu S, Farzaneh SH, Nazertehrani S, Khazaali M, et al. Dose-dependent deleterious and salutary actions of Nrf2 inducer, dh404, in chronic kidney disease. Free Radic Biol Med. 2015
Figure 1.
Proposed mechanism of Nrf2 activation on Agt gene expression in RPTs: Under normal conditions, Nrf2 is bound to Keap1 in the cytoplasm and is subject to ubiquitination and proteasome degradation. Upon exposure to high glucose (HG), oxidative stressor or Nrf2 activators (oltipraz), Nrf2-Keap1 complexes dissociate and Nrf2 translocates to the nucleus. Nrf2 binds to Nrf2-REs in the Agt gene promoter, stimulating Agt gene transcription and intrarenal RAS activation, and leading to the development of hypertension and nephropathy in diabetes. TSS (transcriptional start site)